CYP19A1 and breast cancer: As over 80% of all breast cancers are hormone dependent, anti-estrogens such as tamoxifen or aromatase inhibitors such as Letrozole have been the mainstay of treatment and have been largely responsible for dramatically improving survival rates in this type of breast cancer.